Raymond James & Associates’s Clorox CLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $23.3M | Sell |
142,811
-124,821
| -47% | -$18.5M | 0.01% | 740 |
|
|
2024
Q2 | $36.5M | Buy |
267,632
+66,149
| +33% | +$9.19M | 0.02% | 517 |
|
|
2024
Q1 | $30.8M | Sell |
201,483
-43,377
| -18% | -$6.48M | 0.02% | 582 |
|
|
2023
Q4 | $34.9M | Sell |
244,860
-61,753
| -20% | -$8.23M | 0.03% | 524 |
|
|
2023
Q3 | $40.2M | Buy |
306,613
+22,597
| +8% | +$3.43M | 0.03% | 416 |
|
|
2023
Q2 | $45.2M | Sell |
284,016
-197,652
| -41% | -$31.9M | 0.04% | 386 |
|
|
2023
Q1 | $76.2M | Sell |
481,668
-151,587
| -24% | -$22.7M | 0.07% | 258 |
|
|
2022
Q4 | $88.9M | Buy |
633,255
+79,386
| +14% | +$11.3M | 0.08% | 221 |
|
|
2022
Q3 | $71.1M | Buy |
553,869
+26,869
| +5% | +$3.88M | 0.07% | 242 |
|
|
2022
Q2 | $74.3M | Buy |
527,000
+138,438
| +36% | +$19.8M | 0.07% | 243 |
|
|
2022
Q1 | $54M | Buy |
388,562
+40,892
| +12% | +$6.27M | 0.05% | 336 |
|
|
2021
Q4 | $60.6M | Buy |
347,670
+24,257
| +8% | +$4.04M | 0.05% | 321 |
|
|
2021
Q3 | $53.6M | Buy |
323,413
+8,420
| +3% | +$1.45M | 0.05% | 331 |
|
|
2021
Q2 | $56.7M | Buy |
314,993
+6,559
| +2% | +$1.2M | 0.05% | 312 |
|
|
2021
Q1 | $59.5M | Buy |
308,434
+70,749
| +30% | +$13.6M | 0.06% | 271 |
|
|
2020
Q4 | $48M | Buy |
237,685
+2,189
| +0.9% | +$453K | 0.05% | 298 |
|
|
2020
Q3 | $49.5M | Sell |
235,496
-445
| -0.2% | -$99.1K | 0.06% | 261 |
|
|
2020
Q2 | $51.8M | Buy |
235,941
+4,340
| +2% | +$867K | 0.07% | 238 |
|
|
2020
Q1 | $40.1M | Buy |
231,601
+12,241
| +6% | +$2.02M | 0.06% | 245 |
|
|
2019
Q4 | $33.7M | Buy |
219,360
+3,126
| +1% | +$467K | 0.04% | 375 |
|
|
2019
Q3 | $32.8M | Sell |
216,234
-11,259
| -5% | -$1.78M | 0.05% | 366 |
|
|
2019
Q2 | $34.8M | Buy |
227,493
+10,183
| +5% | +$1.56M | 0.05% | 350 |
|
|
2019
Q1 | $34.9M | Buy |
217,310
+11,289
| +5% | +$1.75M | 0.05% | 336 |
|
|
2018
Q4 | $31.8M | Buy |
206,021
+48,563
| +31% | +$7.57M | 0.06% | 310 |
|
|
2018
Q3 | $23.7M | Buy |
157,458
+4,119
| +3% | +$585K | 0.04% | 469 |
|
|
2018
Q2 | $20.7M | Buy |
153,339
+13,350
| +10% | +$1.65M | 0.03% | 489 |
|
|
2018
Q1 | $18.6M | Buy |
139,989
+4,473
| +3% | +$601K | 0.03% | 504 |
|
|
2017
Q4 | $20.2M | Buy |
135,516
+11,585
| +9% | +$1.58M | 0.04% | 471 |
|
|
2017
Q3 | $16.3M | Sell |
123,931
-1,981
| -2% | -$266K | 0.03% | 527 |
|
|
2017
Q2 | $16.8M | Buy |
125,912
+128
| +0.1% | +$17.3K | 0.04% | 498 |
|
|
2017
Q1 | $17M | Buy |
125,784
+17,871
| +17% | +$2.31M | 0.04% | 458 |
|
|
2016
Q4 | $13M | Buy |
107,913
+2,954
| +3% | +$348K | 0.03% | 520 |
|
|
2016
Q3 | $13.1M | Buy |
104,959
+14,334
| +16% | +$1.88M | 0.04% | 488 |
|
|
2016
Q2 | $12.5M | Sell |
90,625
-13,684
| -13% | -$1.77M | 0.04% | 466 |
|
|
2016
Q1 | $13.2M | Sell |
104,309
-20,683
| -17% | -$2.63M | 0.04% | 431 |
|
|
2015
Q4 | $15.9M | Buy |
124,992
+26,429
| +27% | +$3.28M | 0.06% | 362 |
|
|
2015
Q3 | $11.4M | Buy |
98,563
+1,023
| +1% | +$115K | 0.05% | 440 |
|
|
2015
Q2 | $10.1M | Buy |
97,540
+5,886
| +6% | +$635K | 0.04% | 518 |
|
|
2015
Q1 | $10.1M | Sell |
91,654
-2,814
| -3% | -$305K | 0.04% | 443 |
|
|
2014
Q4 | $9.85M | Buy |
94,468
+161
| +0.2% | +$16.1K | 0.05% | 415 |
|
|
2014
Q3 | $9.06M | Buy |
94,307
+23,797
| +34% | +$2.15M | 0.05% | 391 |
|
|
2014
Q2 | $6.44M | Buy |
70,510
+9,175
| +15% | +$822K | 0.04% | 518 |
|
|
2014
Q1 | $5.4M | Buy |
61,335
+3,504
| +6% | +$308K | 0.04% | 548 |
|
|
2013
Q4 | $5.36M | Buy |
57,831
+617
| +1% | +$55.6K | 0.04% | 506 |
|
|
2013
Q3 | $4.68M | Sell |
57,214
-4,308
| -7% | -$364K | 0.04% | 495 |
|
|
2013
Q2 | $5.12M | Buy |
+61,522
| New | +$5.29M | 0.05% | 419 |
|
Other funds holding CLX
Raymond James & Associates's CLX Position: Q3 2024 in Review
Raymond James & Associates reduced its Clorox (CLX) stake by 47% in Q3 2024, selling an estimated $18.5M and leaving 142,811 shares worth $23.3M. The position accounts for 0.01% of the portfolio, ranked #740.
Raymond James & Associates first reported a position in CLX in Q2 2013 and has held it in 46 quarters since. The position peaked at $88.9M in Q4 2022. 1,152 funds tracked by Wall St. Rank hold CLX as of Q3 2024.
- Raymond James & Associates held 142,811 shares of Clorox worth $23.3M as of Q3 2024.
- Raymond James & Associates sold 124,821 Clorox shares in Q3 2024, an estimated $18.5M.
- Clorox made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #740 holding.
- Raymond James & Associates first reported a position in Clorox in Q2 2013 and has held it in 46 quarters since.
- Raymond James & Associates's Clorox position peaked at $88.9M in Q4 2022.
- 1,152 funds tracked by Wall St. Rank held Clorox as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.